

ioGlutamatergic Neurons™

Human iPSC-derived glutamatergic neurons

Learn more about ioGlutamatergic Neurons

ioCells™

About the cells

ioGlutamatergic Neurons have been precision reprogrammed from human induced pluripotent stem cells (iPSC) using opti-ox™ technology. Within days, cells convert consistently to mature, functional glutamatergic neurons characterised by >80% expression of glutamate transporter genes VGLUT1 and VGLUT2.

Glutamatergic neurons are delivered cryopreserved and ready-to-culture making them a high-quality human model for fundamental research, disease modelling and drug discovery.

Benchtop benefits

QUICK

Ready for experimentation as early as 2 days post-revival and form functional neuronal networks at 17 days.

SCALABLE

Industrial scale quantities at a price point that allows the cells to be used from research to screening scale.

EASY TO USE

Cells arrive programmed to rapidly mature upon revival. One medium is required in a two-phase protocol.

Cells arrive ready to plate



ioGlutamatergic Neurons mature rapidly and form structural neuronal networks over 11 days (upper panel). 100X magnification.

Immunofluorescent staining on post-revival day 11 demonstrates homogenous expression of the pan-neuronal protein, MAP2 and glutamatergic neuron-specific transporter, VGLUT2 (lower panel).



ioGlutamatergic Neurons have highly characterised and defined, so you know exactly what is in every vial.

Get reproducible results from every vial with high lot-to-lot consistency

Whole transcriptome analysis demonstrates high lot-to-lot consistency across three manufactured lots

Bulk RNA-sequencing analysis was performed on three different lots of ioGlutamatergic Neurons on day 0, day 11 and day 18 post-revival. The experimental design included three operators, each handling one lot replicate of the different manufactured lots. (A) A principal component analysis (PCA) to assess gene expression variance between manufactured lots showed a tight clustering of the samples at each timepoint. (B) Differential expression test reveals no statistically significant differentially expressed genes across the three lots at day 11 (|logFC| > 0.5 and FDR < 0.01).

A



B

Differential Gene Expression at day 11

Lot 2 vs Lot 3	0
Lot 1 vs Lot 2	0
Lot 1 vs Lot 3	0
iPSC vs Lot 1	5,735

Robust and scalable cells suitable for high-throughput screening

ioGlutamatergic Neurons show good suitability for high-throughput screening in 384-well format plates

Cytotoxicity CellTiter-Glo® (CTG) and TR-FRET (HTRF®) assays for AKT serine/threonine kinase 1 (AKT) and Huntingtin (HTT) proteins were performed on ioGlutamatergic Neurons in 384-well plates treated with tool compound (cmp) at day 9 post-revival. Compound titration results in a concentration response curve for all three assays (mean±sd of 2 replicates). The CTG assay shows an excellent average signal/background ratio and high suitability for HTS. The HTRF assays show a lower average signal/background ratio, due to lower assay sensitivity, indicating ioGlutamatergic Neurons are also suitable for HTRF assays. Data courtesy of Charles River Laboratories.



Signal/Background	
CellTiter-Glo®	327
HTT HTRF®	1.65
AKT HTRF®	1.95

charles river

ioGlutamatergic Neurons form the isogenic control for ioDisease Model Cells™. This isogenic pairing enables you to make true comparisons in your data, and confidently link genotype to phenotype.

Comparison by microelectrode array (MEA) analysis of wild type ioGlutamatergic Neurons (WT) and Huntington's disease model ioGlutamatergic Neurons HTT 50CAG/WT (HD)

Map of the Firing Rate distribution for (A) WT and (B) HD; Network Firing Rate, recorded for 300 sec. for (C) WT, and (D) HD; 38 days in vitro. During development and maturation, cells in both cultures showed a gradual increase in spontaneous activity. Wild type neurons showed higher spontaneous activity than the disease model. The data demonstrate the value of pairing ioGlutamatergic Neurons with ioDisease Model Cells as an isogenic control to enable disease phenotype characterisation. Data courtesy of Charles River Laboratories.



charles river maxwell BIOSYSTEMS

Product information

Cat code
io1001

Starting material
Human iPSC line

Karyotype
Normal (46, XY)

Seeding compatibility
6, 12, 24, 48, 96 & 384 well plates

Shipping info
Dry ice

Donor
Caucasian adult male
(skin fibroblast)

Vial size
Small: >1 x 10^6 viable cells
Large: >5 x 10^6 viable cells

Quality control
Sterility, protein expression (ICC)
and gene expression (RT-qPCR)

Differentiation method
opti-ox™ cell reprogramming

Recommended seeding density
30,000 cells/cm^2

User storage
LN2 or -150°C

Format
Cryopreserved cells

Product use
ioCells™ are for
research use only

Applications
Drug discovery, neurotoxicology,
high throughput screening,
CRISPR Screening,
3D bioprinting

bit.bio
THE CELL CODING COMPANY

Who we are

bit.bio combines the concepts of cell programming and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.

This is possible with our precision human cellular reprogramming technology opti-ox™ – a gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale

For general information,
email info@bit.bio

To learn more,
visit www.bit.bio